Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 191

Sort by

Sort Order Select

Journal Articles

Increased mTOR activation in idiopathic multicentric Castleman disease

Daniel J. Arenas, Katherine Floess, Dale Kobrin, Ruth-Anne Langan Pai, Maya B. Srkalovic, Mark-Avery Tamakloe, Rozena Rasheed, Jasira Ziglar, Johnson Khor, Sophia A. T. Parente, Sheila K. Pierson, Daniel Martinez, Gerald B. Wertheim, Taku Kambayashi, Joseph Baur, David T. Teachey, David C. Fajgenbaum

Blood (2020) 135 (19): 1673–1684.

https://doi.org/10.1182/blood.2019002792

Published: 2020

Includes: Supplemental data

Journal Articles

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Jihad Aljabban, MMSc, BA, David Chen, BS, Francesca Cottini, MD, Saad Syed, BS, Nabeal Aljabban, BS, Sharjeel Syed, BS, Tiffany Hughes, PhD, David Feldman, BS, Dexter Hadley, MD PhD, Don M. Benson, Jr., MD PhD

Blood (2019) 134 (Supplement_1): 4395.

https://doi.org/10.1182/blood-2019-129699

Published: 2019

Journal Articles

Ywhae/14-3-3ε Expression Promotes Translation Initiation and Protein Synthesis in Multiple Myeloma Regulating Proteasome Load and Contributing to Proteasome Inhibitor Sensitivity/Resistance

Yan Xu, MD, Matthew Ho, PhD, Mehmet Kemal Samur, PhD, Kenneth Wen, Shuhui Deng, MD, Lanting Liu, MD, Tengteng Yu, MD PhD, Zuzana Chyra, PhD, Sanika Derebail, Kenneth C. Anderson, MD, Lugui Qiu, MD PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 5539.

https://doi.org/10.1182/blood-2019-130902

Published: 2019

Journal Articles

A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment

Fernanda Marconi Roversi, Maura Lima Pereira Bueno, undergraduate, Cristiane Okuda Torello, PhD, Fernanda I Della Via, MSc, Renata Giardini Rosa, PhD, Juares Ednaldo Romero Bianco, PhD, Adriana Silva Santos Duarte, PhD, Eduardo M Rego, MD PhD, Alessio Molinari, Maurizio Botta, Sara T Olalla Saad, PhD

Blood (2019) 134 (Supplement_1): 4650.

https://doi.org/10.1182/blood-2019-128959

Published: 2019

Journal Articles

Systems Biology Analysis Identifies Targetable Vulnerability Networks to Proteasome Inhibitors in Multiple Myeloma

Mark B. Meads, PhD, Rafael Renatino Canevarolo, PhD, Praneeth Reddy Sudalagunta, PhD, Paula S. Oliveira, Dario M. Magaletti, Bin Fang, PhD, Maria D Coelho Siqueira Silva, MSc, Amit Kulkarni, PhD, Hongyue Dai, PhD, William S. Dalton, PhDMD, Ion Petre, PhD, John M. Koomen, PhD, Ariosto Siqueira Silva, PhD, Kenneth H. Shain, MD PhD

Blood (2018) 132 (Supplement 1): 950.

https://doi.org/10.1182/blood-2018-99-120269

Published: 2018

Journal Articles

Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1435.

https://doi.org/10.1182/blood-2018-99-118764

Published: 2018

Journal Articles

PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway

Sutapa Sinha, PhD, Tammy Price-Troska, BS, Shulan Tian, MS, PhD, Charla R Secreto, Xiaosheng Wu, MD, Timothy G. Call, MD, Rong He, MD, Sameer A. Parikh, MD, Saad S. Kenderian, MD, Jose F. Leis, MD PhD, Huihuang Yan, PhD, Karen L Rech, MD, Minetta C Liu, MD, Stephen M. Ansell, MD PhD, Neil E. Kay, MD, Wei Ding, MD PhD

Blood (2018) 132 (Supplement 1): 586.

https://doi.org/10.1182/blood-2018-99-112575

Published: 2018

Journal Articles

Inhibition of AKT By MK2206 but Not PI3-Kinase δ By Idelalisib Is Effective Against CLL Cells in an In Vitro Model of the Hypoxic Microenvironment

Yandong Shen, BMedSc (Hon), Kyle R Crassini, MBBS,BE,BSc, Stephen Mulligan, PhDFRACP,FRCPA,MBBS, Richard Christopherson, PhDEmeritus Professor, Oliver Giles Best, PhDBSc

Blood (2017) 130 (Supplement 1): 5340.

https://doi.org/10.1182/blood.V130.Suppl_1.5340.5340

Published: 2017

Journal Articles

Targeting of Glutamine Pathways Restores Sensitivity in Venetoclax Resistant Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Jessica T Leonard, MD, Bill H. Chang, MD PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Marc Loriaux, MD PhD, Pavani Malla, MS

Blood (2017) 130 (Supplement 1): 1264.

https://doi.org/10.1182/blood.V130.Suppl_1.1264.1264

Published: 2017

Journal Articles

Role of Glucose Transporter 1 in Graft-Versus-Host Disease and Graft-Versus-Tumor Effect

Ying Huang, MD PhD, Yiqun Jiao, MD, Peijie Shi, MD PhD, Xiaoli Nie, MD PhD, Wei Huang, MD PhD, Michael Choi, Andrew N Macintyre, Amanda Nichols, Nancie J. MacIver, MD PhD, Nelson J. Chao, MDM.B.A, Jeffrey Rathmell, PhD, Benny J. Chen, MD

Blood (2017) 130 (Supplement 1): 1891.

https://doi.org/10.1182/blood.V130.Suppl_1.1891.1891

Published: 2017

Journal Articles

IGF Signaling Predicts Outcomes and Is a Promising Target Therapy for Acute Myeloid Leukemia

Juan Luiz Coelho-Silva, BSc, MSc, João Agostinho Machado-Neto, BSc, Jaqueline Cristina Fernandes, BSc, MSc, Ana Silvia G de Lima, PhD, Priscila Santos Scheucher, PhD, Eduardo Magalhães Rego, MDPhD, Fabiola Traina, MD PhD

Blood (2017) 130 (Supplement 1): 3966.

https://doi.org/10.1182/blood.V130.Suppl_1.3966.3966

Published: 2017

Journal Articles

CDK7 Inhibitor THZ1 Inhibits Glycolytic Metabolism By Suppressing HIF1α Activity in Chronic Lymphocytic Leukemia

Shuchao Qin, MBBS, Austin Young Shull, Qimei Han, MBBS, Lirong Pei, Farrukh T. Awan, MD MS, Wei Xu, Jianyong Li, MD PhD, Huidong Shi

Blood (2017) 130 (Supplement 1): 3811.

https://doi.org/10.1182/blood.V130.Suppl_1.3811.3811

Published: 2017

Journal Articles

A Phase II Clinical Trial of the Pan PI3K Inhibitor, Buparlisib, for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia: Canadian Cancer Trials Group IND.216

Sarit Assouline, MD, Lilian Amrein, PhD, Versha Banerji, MD FRCP, Stephen Caplan, MD, Carolyn Jane Owen, MD FRCPC, Wanda Hasegawa, MD, Sue Robinson, MD, Sudeep Shavikumar, MD, Anca Prica, MD FRCP(C), Anthea Peters, MSc, MD FRCPC, Linda Hagerman, Laura Rodriguez, Tanya Skamene, MD, Lawrence Panasci, MD, Bingshu E. Chen, Annette E Hay

Blood (2017) 130 (Supplement 1): 4319.

https://doi.org/10.1182/blood.V130.Suppl_1.4319.4319

Published: 2017

Journal Articles

RSK Inhibition Induces Metaphase Arrest and Apoptosis in Acute Myeloid Leukemia Cells

Hee-Don Chae, PhD, Ritika Dutta, BS, Bruce Tiu, Kara L. Davis, DO, Norman J. Lacayo, MD, Kathleen M. Sakamoto, MD PhD

Blood (2017) 130 (Supplement 1): 2530.

https://doi.org/10.1182/blood.V130.Suppl_1.2530.2530

Published: 2017

Journal Articles

PCT3, a Combination of Active Steroidal Saponins from the Paris Forrestii (Takht.) H. Li, Displays Potent Activity Against Acute Myeloid Leukemia By Suppressing the PBX1/RNF6/AKT/mTOR Signaling Pathway

Qin Lu, MD, Yunjing Zheng, MD, Yuehu Wang, PhD, Jian Pan, PhD, Xinliang Mao, MD PhD, Shaoyan Hu, MD PhD

Blood (2017) 130 (Supplement 1): 2533.

https://doi.org/10.1182/blood.V130.Suppl_1.2533.2533

Published: 2017

Journal Articles

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

Lucia Mazzacurati, Que T. Lambert, Robert J. Collins, Holly K. Koblish, PhD, Bruce Ruggeri, Matthew C. Stubbs, Gary W. Reuther, PhD

Blood (2017) 130 (Supplement 1): 1661.

https://doi.org/10.1182/blood.V130.Suppl_1.1661.1661

Published: 2017

Journal Articles

Ywhae Located on Chromosome 17p13 Promotes Myeloma Cells Proliferation Via Induction of Anti-Apoptosis and Survival Signaling Pathways

Blood (2017) 130 (Supplement 1): 1755.

https://doi.org/10.1182/blood.V130.Suppl_1.1755.1755

Published: 2017

Journal Articles

Dysregulation of Follistatin Promotes Leukemogenesis in Acute Myeloid Leukemia

Alex Bai-Liang He, PhD, Nelson Ka Lam Ng, BA, Chae Yin Cher, Alan WL To, Chunxiao Zhang, Stephen SY Lam, Anskar Leung, MD PhD

Blood (2017) 130 (Supplement 1): 4982.

https://doi.org/10.1182/blood.V130.Suppl_1.4982.4982

Published: 2017

Journal Articles

Phosphoproteomic Landscaping Unveils Constitutive cKIT Activation in Human Erythroblasts from Polycythemia Vera (PV) Patients

Lilian Varricchio, PhD, Giulia Federici, PhD, Francesca Masiello, MS, Fabrizio Martelli, PhD, Mario Falchi, PhD, Orietta Picconi, Gabriella Girelli, MD, Agostino Tafuri, MD, Emanuel Petricoin III, PhD, Ann Zeuner, PhD, Anna Rita Migliaccio, PhD

Blood (2016) 128 (22): 399.

https://doi.org/10.1182/blood.V128.22.399.399

Published: 2016

Journal Articles

The RET Receptor Tyrosine Kinase Promotes Acute Myeloid Leukemia through Protection of FLT3-ITD Mutants from Autophagic Degradation

Saskia Rudat, MSc, Anja Pfaus, MSc, Claudia Bühler, MD, Sophie Rabe, MSc, Lars Bullinger, MD, Stefan Gröschel, MD, Stephen M. Sykes, PhD, Michael D. Milsom, PhD, Jana M. Ellegast, MD, Stefan Fröhling, MD, Claudia Scholl, MD

Blood (2016) 128 (22): 2849.

https://doi.org/10.1182/blood.V128.22.2849.2849

Published: 2016

NARROW

Increased mTOR activation in idiopathic multicentric Castleman disease

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Ywhae/14-3-3ε Expression Promotes Translation Initiation and Protein Synthesis in Multiple Myeloma Regulating Proteasome Load and Contributing to Proteasome Inhibitor Sensitivity/Resistance

A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment

Systems Biology Analysis Identifies Targetable Vulnerability Networks to Proteasome Inhibitors in Multiple Myeloma

Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia

PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway

Inhibition of AKT By MK2206 but Not PI3-Kinase δ By Idelalisib Is Effective Against CLL Cells in an In Vitro Model of the Hypoxic Microenvironment

Targeting of Glutamine Pathways Restores Sensitivity in Venetoclax Resistant Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Role of Glucose Transporter 1 in Graft-Versus-Host Disease and Graft-Versus-Tumor Effect

IGF Signaling Predicts Outcomes and Is a Promising Target Therapy for Acute Myeloid Leukemia

CDK7 Inhibitor THZ1 Inhibits Glycolytic Metabolism By Suppressing HIF1α Activity in Chronic Lymphocytic Leukemia

A Phase II Clinical Trial of the Pan PI3K Inhibitor, Buparlisib, for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia: Canadian Cancer Trials Group IND.216

RSK Inhibition Induces Metaphase Arrest and Apoptosis in Acute Myeloid Leukemia Cells

PCT3, a Combination of Active Steroidal Saponins from the Paris Forrestii (Takht.) H. Li, Displays Potent Activity Against Acute Myeloid Leukemia By Suppressing the PBX1/RNF6/AKT/mTOR Signaling Pathway

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

Ywhae Located on Chromosome 17p13 Promotes Myeloma Cells Proliferation Via Induction of Anti-Apoptosis and Survival Signaling Pathways

Dysregulation of Follistatin Promotes Leukemogenesis in Acute Myeloid Leukemia

Phosphoproteomic Landscaping Unveils Constitutive cKIT Activation in Human Erythroblasts from Polycythemia Vera (PV) Patients

The RET Receptor Tyrosine Kinase Promotes Acute Myeloid Leukemia through Protection of FLT3-ITD Mutants from Autophagic Degradation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only